Correlation Between Entrada Therapeutics and Vivendi SE

Can any of the company-specific risk be diversified away by investing in both Entrada Therapeutics and Vivendi SE at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Entrada Therapeutics and Vivendi SE into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Entrada Therapeutics and Vivendi SE, you can compare the effects of market volatilities on Entrada Therapeutics and Vivendi SE and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Entrada Therapeutics with a short position of Vivendi SE. Check out your portfolio center. Please also check ongoing floating volatility patterns of Entrada Therapeutics and Vivendi SE.

Diversification Opportunities for Entrada Therapeutics and Vivendi SE

-0.41

Correlation Coefficient

Entrada Therapeutics  Vivendi SE

Very good diversification

The 3 months correlation between Entrada and Vivendi is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Entrada Therapeutics and Vivendi SE in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Vivendi SE and Entrada Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Entrada Therapeutics are associated (or correlated) with Vivendi SE. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Vivendi SE has no effect on the direction of Entrada Therapeutics i.e., Entrada Therapeutics and Vivendi SE go up and down completely randomly.

Pair Corralation between Entrada Therapeutics and Vivendi SE

Given the investment horizon of 90 days Entrada Therapeutics is expected to under-perform the Vivendi SE. But the stock apears to be less risky and, when comparing its historical volatility, Entrada Therapeutics is 20.24 times less risky than Vivendi SE. The stock trades about -0.12 of its potential returns per unit of risk. The Vivendi SE is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest  925.00  in Vivendi SE on September 27, 2024 and sell it today you would lose (325.00) from holding Vivendi SE or give up 35.14% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Entrada Therapeutics  vs.  Vivendi SE

Entrada Therapeutics

Risk-Adjusted Performance

3 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Entrada Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating fundamental indicators, Entrada Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Vivendi SE

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Vivendi SE are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Vivendi SE reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Entrada Therapeutics and Vivendi SE

The main advantage of trading using opposite Entrada Therapeutics and Vivendi SE positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Entrada Therapeutics position performs unexpectedly, Vivendi SE can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vivendi SE will offset losses from the drop in Vivendi SE's long position.

The idea behind Entrada Therapeutics and Vivendi SE pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.